[{"orgOrder":0,"company":"Renalys Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"JAPAN","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Sparsentan","moa":"Endothelin receptor ET-A | Type-1 angiotensin II receptor","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Renalys Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Renalys Pharma \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Renalys Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Renalys Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"JAPAN","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Sparsentan","moa":"Endothelin receptor ET-A | Type-1 angiotensin II receptor","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Renalys Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Renalys Pharma \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Renalys Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Renalys Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"JAPAN","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Sparsentan","moa":"Endothelin receptor ET-A | Type-1 angiotensin II receptor","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Renalys Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Renalys Pharma \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Renalys Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Renalys Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"JAPAN","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Sparsentan","moa":"Endothelin receptor ET-A | Type-1 angiotensin II receptor","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Renalys Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Renalys Pharma \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Renalys Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Renalys Pharma","sponsor":"Catalys Pacific","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"JAPAN","productType":"Miscellaneous","year":"2024","type":"Series A Financing","leadProduct":"Sparsentan","moa":"Endothelin receptor ET-A | Type-1 angiotensin II receptor","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Renalys Pharma","amount2":0.040000000000000001,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Nephrology","amount2New":0.040000000000000001,"dosageForm":"Tablet, Film Coated","sponsorNew":"Renalys Pharma \/ Catalys Pacific","highestDevelopmentStatusID":"15","companyTruncated":"Renalys Pharma \/ Catalys Pacific"},{"orgOrder":0,"company":"Renalys Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"JAPAN","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Sparsentan","moa":"Endothelin receptor ET-A | Type-1 angiotensin II receptor","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Renalys Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Renalys Pharma \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Renalys Pharma \/ Undisclosed"},{"orgOrder":0,"company":"University of Leicester","sponsor":"Travere Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Sparsentan","moa":"Endothelin receptor ET-A | Type-1 angiotensin II receptor","graph1":"Nephrology","graph2":"Phase II","graph3":"University of Leicester","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"University of Leicester \/ Travere Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"University of Leicester \/ Travere Therapeutics"},{"orgOrder":0,"company":"University of Edinburgh","sponsor":"Travere Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Sparsentan","moa":"Endothelin receptor ET-A | Type-1 angiotensin II receptor","graph1":"Immunology","graph2":"Phase II","graph3":"University of Edinburgh","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Edinburgh \/ Travere Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"University of Edinburgh \/ Travere Therapeutics"},{"orgOrder":0,"company":"Travere Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Sparsentan","moa":"Endothelin receptor ET-A | Type-1 angiotensin II receptor","graph1":"Nephrology","graph2":"Phase III","graph3":"Travere Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Travere Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Travere Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Travere Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Sparsentan","moa":"Endothelin receptor ET-A | Type-1 angiotensin II receptor","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Travere Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Travere Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Travere Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Travere Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Sparsentan","moa":"Endothelin receptor ET-A | Type-1 angiotensin II receptor","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Travere Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Travere Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Travere Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Travere Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Sparsentan","moa":"Endothelin receptor ET-A | Type-1 angiotensin II receptor","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Travere Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Travere Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Travere Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Travere Therapeutics","sponsor":"Ligand Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Sparsentan","moa":"Endothelin receptor ET-A | Type-1 angiotensin II receptor","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Travere Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Travere Therapeutics \/ Ligand Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Travere Therapeutics \/ Ligand Pharmaceuticals"},{"orgOrder":0,"company":"Travere Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Sparsentan","moa":"Endothelin receptor ET-A | Type-1 angiotensin II receptor","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Travere Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Travere Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Travere Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Travere Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Sparsentan","moa":"Endothelin receptor ET-A | Type-1 angiotensin II receptor","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Travere Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Travere Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Travere Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Travere Therapeutics","sponsor":"CSL Vifor","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Sparsentan","moa":"Endothelin receptor ET-A | Type-1 angiotensin II receptor","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Travere Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Travere Therapeutics \/ CSL Vifor","highestDevelopmentStatusID":"15","companyTruncated":"Travere Therapeutics \/ CSL Vifor"},{"orgOrder":0,"company":"Travere Therapeutics","sponsor":"CSL Vifor","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Sparsentan","moa":"Endothelin receptor ET-A | Type-1 angiotensin II receptor","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Travere Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Travere Therapeutics \/ CSL Vifor","highestDevelopmentStatusID":"15","companyTruncated":"Travere Therapeutics \/ CSL Vifor"},{"orgOrder":0,"company":"Travere Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Sparsentan","moa":"Endothelin receptor ET-A | Type-1 angiotensin II receptor","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Travere Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Travere Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Travere Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Travere Therapeutics","sponsor":"Jefferies","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Public Offering","leadProduct":"Sparsentan","moa":"Endothelin receptor ET-A | Type-1 angiotensin II receptor","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Travere Therapeutics","amount2":0.20000000000000001,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Nephrology","amount2New":0.23000000000000001,"dosageForm":"Tablet","sponsorNew":"Travere Therapeutics \/ Jefferies","highestDevelopmentStatusID":"15","companyTruncated":"Travere Therapeutics \/ Jefferies"},{"orgOrder":0,"company":"Travere Therapeutics","sponsor":"Jefferies","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Public Offering","leadProduct":"Sparsentan","moa":"Endothelin receptor ET-A | Type-1 angiotensin II receptor","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Travere Therapeutics","amount2":0.23000000000000001,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Nephrology","amount2New":0.23000000000000001,"dosageForm":"Tablet","sponsorNew":"Travere Therapeutics \/ Jefferies","highestDevelopmentStatusID":"15","companyTruncated":"Travere Therapeutics \/ Jefferies"},{"orgOrder":0,"company":"Travere Therapeutics","sponsor":"Ligand Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Sparsentan","moa":"Endothelin receptor ET-A | Type-1 angiotensin II receptor","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Travere Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Travere Therapeutics \/ Ligand Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Travere Therapeutics \/ Ligand Pharmaceuticals"},{"orgOrder":0,"company":"Travere Therapeutics","sponsor":"Renalys Pharma","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Licensing Agreement","leadProduct":"Sparsentan","moa":"Endothelin receptor ET-A | Type-1 angiotensin II receptor","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Travere Therapeutics","amount2":0.12,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Nephrology","amount2New":0.12,"dosageForm":"Tablet","sponsorNew":"Travere Therapeutics \/ Renalys Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Travere Therapeutics \/ Renalys Pharma"},{"orgOrder":0,"company":"Travere Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Sparsentan","moa":"Endothelin receptor ET-A | Type-1 angiotensin II receptor","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Travere Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Travere Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Travere Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Travere Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Sparsentan","moa":"Endothelin receptor ET-A | Type-1 angiotensin II receptor","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Travere Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Travere Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Travere Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Travere Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Sparsentan","moa":"Endothelin receptor ET-A | Type-1 angiotensin II receptor","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Travere Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Travere Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Travere Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Travere Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Sparsentan","moa":"Endothelin receptor ET-A | Type-1 angiotensin II receptor","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Travere Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Travere Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Travere Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Travere Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Sparsentan","moa":"Endothelin receptor ET-A | Type-1 angiotensin II receptor","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Travere Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Travere Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Travere Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Travere Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Sparsentan","moa":"Endothelin receptor ET-A | Type-1 angiotensin II receptor","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Travere Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Travere Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Travere Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Travere Therapeutics","sponsor":"CSL Vifor","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Sparsentan","moa":"Endothelin receptor ET-A | Type-1 angiotensin II receptor","graph1":"Nephrology","graph2":"Phase III","graph3":"Travere Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Travere Therapeutics \/ CSL Vifor","highestDevelopmentStatusID":"10","companyTruncated":"Travere Therapeutics \/ CSL Vifor"},{"orgOrder":0,"company":"Travere Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Sparsentan","moa":"Endothelin receptor ET-A | Type-1 angiotensin II receptor","graph1":"Nephrology","graph2":"Phase III","graph3":"Travere Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Travere Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Travere Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Travere Therapeutics","sponsor":"CSL Vifor","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Sparsentan","moa":"Endothelin receptor ET-A | Type-1 angiotensin II receptor","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Travere Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Travere Therapeutics \/ CSL Vifor","highestDevelopmentStatusID":"15","companyTruncated":"Travere Therapeutics \/ CSL Vifor"},{"orgOrder":0,"company":"Travere Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Sparsentan","moa":"Endothelin receptor ET-A | Type-1 angiotensin II receptor","graph1":"Nephrology","graph2":"Phase III","graph3":"Travere Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Travere Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Travere Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Travere Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Sparsentan","moa":"Endothelin receptor ET-A | Type-1 angiotensin II receptor","graph1":"Nephrology","graph2":"Phase III","graph3":"Travere Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Travere Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Travere Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Travere Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Sparsentan","moa":"Endothelin receptor ET-A | Type-1 angiotensin II receptor","graph1":"Nephrology","graph2":"Phase III","graph3":"Travere Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Travere Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Travere Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Travere Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Sparsentan","moa":"Endothelin receptor ET-A | Type-1 angiotensin II receptor","graph1":"Nephrology","graph2":"Phase III","graph3":"Travere Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Travere Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Travere Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Travere Therapeutics","sponsor":"CSL Vifor","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Collaboration","leadProduct":"Sparsentan","moa":"Endothelin receptor ET-A | Type-1 angiotensin II receptor","graph1":"Nephrology","graph2":"Phase III","graph3":"Travere Therapeutics","amount2":0.19,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0.19,"dosageForm":"Tablet, Film Coated","sponsorNew":"Travere Therapeutics \/ Vifor Pharma","highestDevelopmentStatusID":"10","companyTruncated":"Travere Therapeutics \/ Vifor Pharma"},{"orgOrder":0,"company":"Travere Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Sparsentan","moa":"Endothelin receptor ET-A | Type-1 angiotensin II receptor","graph1":"Nephrology","graph2":"Phase III","graph3":"Travere Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Travere Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Travere Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Travere Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Sparsentan","moa":"Endothelin receptor ET-A | Type-1 angiotensin II receptor","graph1":"Nephrology","graph2":"Phase III","graph3":"Travere Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Travere Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Travere Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Travere Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Sparsentan","moa":"Endothelin receptor ET-A | Type-1 angiotensin II receptor","graph1":"Nephrology","graph2":"Phase III","graph3":"Travere Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Travere Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Travere Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Travere Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Sparsentan","moa":"Endothelin receptor ET-A | Type-1 angiotensin II receptor","graph1":"Nephrology","graph2":"Phase III","graph3":"Travere Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Travere Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Travere Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Travere Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Sparsentan","moa":"Endothelin receptor ET-A | Type-1 angiotensin II receptor","graph1":"Undisclosed","graph2":"Phase I","graph3":"Travere Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Travere Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Travere Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Travere Therapeutics","sponsor":"Jefferies","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Public Offering","leadProduct":"Sparsentan","moa":"Endothelin receptor ET-A | Type-1 angiotensin II receptor","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Travere Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Nephrology","amount2New":0.23000000000000001,"dosageForm":"Undisclosed","sponsorNew":"Travere Therapeutics \/ Jefferies","highestDevelopmentStatusID":"15","companyTruncated":"Travere Therapeutics \/ Jefferies"},{"orgOrder":0,"company":"Travere Therapeutics","sponsor":"Jefferies","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Public Offering","leadProduct":"Sparsentan","moa":"Endothelin receptor ET-A | Type-1 angiotensin II receptor","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Travere Therapeutics","amount2":0.13,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Nephrology","amount2New":0.23000000000000001,"dosageForm":"Undisclosed","sponsorNew":"Travere Therapeutics \/ Jefferies","highestDevelopmentStatusID":"15","companyTruncated":"Travere Therapeutics \/ Jefferies"},{"orgOrder":0,"company":"Travere Therapeutics","sponsor":"Jefferies","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Public Offering","leadProduct":"Sparsentan","moa":"Endothelin receptor ET-A | Type-1 angiotensin II receptor","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Travere Therapeutics","amount2":0.14000000000000001,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Nephrology","amount2New":0.23000000000000001,"dosageForm":"Undisclosed","sponsorNew":"Travere Therapeutics \/ Jefferies","highestDevelopmentStatusID":"15","companyTruncated":"Travere Therapeutics \/ Jefferies"},{"orgOrder":0,"company":"Travere Therapeutics","sponsor":"CSL Vifor","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Sparsentan","moa":"Endothelin receptor ET-A | Type-1 angiotensin II receptor","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Travere Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Travere Therapeutics \/ Vifor Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Travere Therapeutics \/ Vifor Pharma"},{"orgOrder":0,"company":"Travere Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Sparsentan","moa":"Endothelin receptor ET-A | Type-1 angiotensin II receptor","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Travere Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Travere Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Travere Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"CSL","sponsor":"Travere Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"AUSTRALIA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Sparsentan","moa":"Endothelin receptor ET-A | Type-1 angiotensin II receptor","graph1":"Nephrology","graph2":"Phase III","graph3":"CSL","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"CSL \/ Travere Therapeutics","highestDevelopmentStatusID":"10","companyTruncated":"CSL \/ Travere Therapeutics"},{"orgOrder":0,"company":"Renalys Pharma","sponsor":"Chugai Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"JAPAN","productType":"Miscellaneous","year":"2025","type":"Acquisition","leadProduct":"Sparsentan","moa":"Endothelin receptor ET-A | Type-1 angiotensin II receptor","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Renalys Pharma","amount2":0.20000000000000001,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Nephrology","amount2New":0.20000000000000001,"dosageForm":"Tablet, Film Coated","sponsorNew":"Renalys Pharma \/ Chugai Pharmaceutical","highestDevelopmentStatusID":"15","companyTruncated":"Renalys Pharma \/ Chugai Pharmaceutical"},{"orgOrder":0,"company":"Travere Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Sparsentan","moa":"Endothelin receptor ET-A | Type-1 angiotensin II receptor","graph1":"Nephrology","graph2":"Phase IV","graph3":"Travere Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Travere Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Travere Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Brigham and Women's Hospital","sponsor":"Travere Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Sparsentan","moa":"Endothelin receptor ET-A | Type-1 angiotensin II receptor","graph1":"Nephrology","graph2":"Phase I","graph3":"Brigham and Women's Hospital","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Brigham and Women's Hospital \/ Travere Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"Brigham and Women's Hospital \/ Travere Therapeutics"}]
Find Clinical Drug Pipeline Developments & Deals for Sparsentan
Filters
×
FILTER:
Company Name
Year
DEALS // DEV.
Country
Sponsor
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Reset All
